Baxter Bros Inc. acquired a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 18,827 shares of the medical research company's stock, valued at approximately $9,439,000. Thermo Fisher Scientific makes up approximately 1.1% of Baxter Bros Inc.'s portfolio, making the stock its 26th biggest position.
A number of other institutional investors have also made changes to their positions in the company. Legacy Wealth Managment LLC ID grew its holdings in Thermo Fisher Scientific by 78.6% during the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company's stock valued at $25,000 after purchasing an additional 22 shares in the last quarter. Allied Private Wealth LLC acquired a new position in Thermo Fisher Scientific in the 2nd quarter worth $26,000. High Note Wealth LLC boosted its position in Thermo Fisher Scientific by 170.6% in the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company's stock valued at $27,000 after buying an additional 29 shares during the last quarter. Swiss RE Ltd. acquired a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at about $28,000. Finally, JPL Wealth Management LLC purchased a new stake in shares of Thermo Fisher Scientific during the third quarter worth about $28,000. 89.23% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling
In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the company's stock in a transaction dated Monday, July 27th. The shares were sold at an average price of $565.00, for a total value of $226,000.00. Following the completion of the transaction, the chief operating officer owned 24,651 shares in the company, valued at approximately $13,927,815. This represents a 1.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 4,608 shares of the firm's stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $586.12, for a total transaction of $2,700,840.96. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 52,053 shares of company stock valued at $30,643,589 in the last three months. 0.33% of the stock is owned by corporate insiders.
Wall Street Analyst Weigh In
A number of research analysts recently commented on the company. Robert W. Baird reduced their price target on Thermo Fisher Scientific from $653.00 to $639.00 and set an "outperform" rating for the company in a report on Friday, April 24th. Barclays upped their target price on Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an "overweight" rating in a research report on Friday, July 24th. Royal Bank Of Canada increased their target price on Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a "sector perform" rating in a research note on Friday, July 24th. Wolfe Research began coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They issued an "outperform" rating and a $535.00 price target for the company. Finally, Sanford C. Bernstein initiated coverage on shares of Thermo Fisher Scientific in a report on Friday, June 26th. They issued a "market perform" rating and a $520.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $619.41.
Check Out Our Latest Stock Analysis on Thermo Fisher Scientific
Thermo Fisher Scientific Stock Performance
Thermo Fisher Scientific stock opened at $586.62 on Tuesday. The company has a market cap of $216.90 billion, a PE ratio of 31.56, a P/E/G ratio of 2.39 and a beta of 0.84. Thermo Fisher Scientific Inc. has a 12 month low of $435.27 and a 12 month high of $643.99. The company has a fifty day moving average price of $531.72 and a two-hundred day moving average price of $508.48. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating the consensus estimate of $5.71 by $0.32. The business had revenue of $11.99 billion during the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company's quarterly revenue was up 10.5% on a year-over-year basis. During the same period in the previous year, the business posted $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Research analysts expect that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.
Thermo Fisher Scientific Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be given a $0.47 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 10.11%.
About Thermo Fisher Scientific
(
Free Report)
Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.
Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
